CCA
UTHR icon

Catalyst Capital Advisors’s United Therapeutics UTHR Stock Holding History

Catalyst Capital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-873
Closed -$103K – 533
2016
Q3 		$103K Sell
873
-45
-5% -$5.41K 0.01% 276
2016
Q2 		$97K Buy
918
+99
+12% +$11K 0.02% 303
2016
Q1 		$91K Buy
+819
New +$104K 0.02% 298
2015
Q3 		– Sell
-1,378
Closed -$240K – 618
2015
Q2 		$240K Buy
+1,378
New +$248K 0.03% 296
2014
Q3 		– Sell
-8,248
Closed -$730K – 486
2014
Q2 		$730K Buy
+8,248
New +$793K 0.12% 199

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Catalyst Capital Advisors's UTHR Position: Q4 2016 in Review

Catalyst Capital Advisors sold out of United Therapeutics (UTHR) in Q4 2016, closing a stake of 873 shares — an estimated $103K sold.

Catalyst Capital Advisors first reported a position in UTHR in Q2 2014 and held it in 5 quarters. The position peaked at $730K in Q2 2014. 406 funds tracked by Wall St. Rank hold UTHR as of Q4 2016.

  • Catalyst Capital Advisors reported no remaining United Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Catalyst Capital Advisors sold 873 United Therapeutics shares in Q4 2016, an estimated $103K.
  • Catalyst Capital Advisors first reported a position in United Therapeutics in Q2 2014 and held it in 5 quarters.
  • Catalyst Capital Advisors's United Therapeutics position peaked at $730K in Q2 2014.
  • 406 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2016.

Based on Catalyst Capital Advisors's 13F filing for Q4 2016, filed 8 Feb 2017.